Letter to the Editor: To treat or not to treat study: Comparative group inclusion considerations
Publication date: Available online 30 January 2020Source: Multiple Sclerosis and Related DisordersAuthor(s): Lisa B. Grech, Michelle Allan, Ernest Butler
Side-effects of bexarotene rule out use but trial suggests other drugs may halt multiple sclerosisDoctors believe they are closer to a treatment for multiple sclerosis after discovering a drug that repairs the coatings around nerves that are damaged by the disease.A clinical trial of the cancer drug bexarotene showed that it repaired the protective myelin sheaths that MS destroys. The loss of myelin causes a range of neurological problems including balance, vision and muscle disorders, and ultimately, disability.Continue reading...
Publication date: December 2020Source: Journal of Transport &Health, Volume 19Author(s): Stephanie L. Silveira, Robert W. Motl
Conclusion: The results showed that the MLQ is a valid and reliable measure for assessing meaning in life that can be applied in research on meaning in life among other patient populations. PMID: 32963500 [PubMed - in process]
ConclusionIdentifying PwRRMS with risk-seeking behavior would be crucial to implementing specific educational strategies to manage information on disease prognosis, treatment expectations, and safety risk knowledge.
ConclusionGiven the importance of MTCs for healthcare decision-making, it is imperative that reporting of methods, results and assumptions is clear and transparent to allow accurate interpretation of findings. For MTCs to be relevant, the choice of outcome measures should reflect clinical practice. Combination of treatments or of outcomes measured at different points of time should be avoided, as should imputation without justification. Furthermore, all approved treatment options should be included and updates of MTCs should be conducted when data for new treatments are published.
Conclusions The TUG—an easy and unexpansive measure of disability—is associated with the degree of neuroaxonal damage, as measured by sNfL, in patients with MS with low level of disability. These findings confirm the validity of the TUG as a reliable bedside measure of global neurologic disability as a result of neuroaxonal damage.
In conclusion, diterpenes and their derivatives could be one of the promising compounds for the treatment of NLRP3-mediated inflammatory diseases and disorders.
Multiple sclerosis (MS) is caused by an overactive immune system, which results in scarring of the coating that surrounds the nerves (myelin) in the brain, eyes, and spinal cord. An estimated 1 million individuals in the United States and 2,500,000 worldwide live with MS. Many individuals with MS will at some point experience vision problems. These vision problems can be managed by medical and rehabilitation treatment. This Information/Education Page was developed to help individuals living with MS, their family, and caregivers to better understand vision problems that often appear during the course of the disease, as well...